Harlequin. As a scientist you clearly understand the the significance of why the phrase non-significant is used but in the current market anything that looks or sounds negative is amplified and priced accordingly. The market sells and shifts its gaze elsewhere. I fear the SP will languish for a while now. Lets reverse the old adage 'sell on rumour, buy on news'
The company raised £7m just 3 months ago so hopefully funded for a while. The RNS has to be couched in cold scientific language and includes phrases that sound negative, ie non-significant but for a trial outcome this is very good. Its just not the 'DDDD's magic pill cures IBS, covid and world famine' News of the World type headline the market wants. What is clear is that time is now needed to get through the phase 3 trials. Stick or fold, its each investors own decision.
Hardly news I know but the following from Sky News. Small restaurants complain about high commissions from Deliveroo and Just Eat-up to 35%. 'Small restaurants are accusing Deliveroo of unfairness and claim the delivery app is charging some large chain restaurants significantly lower commission rates than many small independent partners'.
Alwaysone. If you are right about the ipo figure for STEM, circa £300m and it transfers for £3m ( which I equate to approx 1.5p/share) then after the ipo each share will be worth £1.50/share. Time to stock up!!!!! I would be careful about quoting an ipo value unless you have knowledge the rest of us don't. I appreciate its an opinion but others might read it differently. Fingers crossed.
The only figure applied to STEM is circa £3m which is the cost to date to TILS of developing the technology. It will be transferred into a new co at this figure, but this is not necessarily what it is worth, that will be determined by the market on flotation. I have no doubt the DoB have a view of what STEM is worth but haven't said openly what that might be. I assume before the float/IPO a value will be indicated as is the case for most IPOs.
For info, thought people in this share might like to see BD's post on the SAE board this morning. Leave you to make your own minds up as to his motives for his posts here today: Yeah same mate I need to get to 32.p just to break even l. Here for the long term tho. Think big-
Almost certainly what they have spent on Stem to date. It is perfectly legit to value an asset for accounting purposes at cost. The risk is that if it is not regularly re-valued and suddenly has a massive increase in value it will show up in the P&L and will give rise to a tax liability. I assume that was what the company was checking. Once it is in another company the 'profit' will occur in that company.
See note from RNS below. Book value £3m. This is not necessarily its MV which will be established by an IPO. Divi in Specie is a divi in value not cash. As far as I am aware the BoD have not given an opinion of MV from Stem
The Demerger will be implemented by Tiziana declaring a dividend in specie on the Tiziana Shares equal to the book value (of approximately £3.07m) of Tiziana's shareholding in StemPrintER Sciences, the entity within the Tiziana group which holds all of the assets and intellectual property relating to StemPrintER and SPARE and £1.0 million in cash.
Calling it short selling is just a cover for market manipulation. If a firm is deliberately managing an SP to its own or client's advantage it is sharp practice. Years ago Guinness and its CEO, a fellow called Saunders, were found guilty of market manipulation and its still going on. Its no better than a cartel in other industries. Should be banned.